Finland· FI-REL-REL4881
Hivid
A zalcitabine product, registered in Finland by F.Hoffmann-La Roche Ltd. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Zalcitabine is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AF03 (zalcitabine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 1 of them publish a price we can compare per daily dose
Zalcitabine · ATC J05AF03
2 / 19 countries
- Finlandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Manufacturer
- F.Hoffmann-La Roche Ltd
- Country
- Finland (FI)
- ATC code
- J05AF03
- ATC class
- Zalcitabine
- Defined daily dose
- 2.25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
100 interactions on record for zalcitabine.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zalcitabine · interactions on record
100 records
- 7 severe
- 84 moderate
- 9 minor
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AF03
Zalcitabine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d23d0b41-96ad-4513-bd30-7ddea69a136f GET /v1/drugs/d23d0b41-96ad-4513-bd30-7ddea69a136f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "2.25",
"form": "tabletti",
"route": null,
"ddd_unit": "mg",
"strength": "0.375 mg",
"atc_label": "tsalsitabiini",
"ma_number": "10885",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL4881",
"authorised_at": "1993-01-13"
}See everything about zalcitabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.